津药药业
(600488)
| 流通市值：42.69亿 | | | 总市值：42.77亿 |
| 流通股本：10.92亿 | | | 总股本：10.94亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 863,769,688.7 | 3,782,826,621.15 | 2,837,778,648.87 | 2,023,258,856.62 |
| 营业收入 | 863,769,688.7 | 3,782,826,621.15 | 2,837,778,648.87 | 2,023,258,856.62 |
| 二、营业总成本 | 759,000,837.68 | 3,590,176,148.18 | 2,593,674,378.54 | 1,821,004,304.04 |
| 营业成本 | 475,513,886.07 | 2,026,643,080.21 | 1,450,405,266.28 | 995,598,853.89 |
| 税金及附加 | 9,997,202.78 | 48,528,780.28 | 36,896,861.82 | 25,694,451.92 |
| 销售费用 | 155,819,677.3 | 1,050,907,596.03 | 775,184,397.81 | 583,107,396.73 |
| 管理费用 | 75,241,100.38 | 285,759,308.12 | 194,736,913.79 | 125,000,445.68 |
| 研发费用 | 38,968,129.61 | 161,126,459.43 | 124,904,451.99 | 84,927,699.54 |
| 财务费用 | 3,460,841.54 | 17,210,924.11 | 11,546,486.85 | 6,675,456.28 |
| 其中:利息费用 | 8,463,756.68 | 36,682,125.73 | 29,055,217 | 21,420,074.81 |
| 其中:利息收入 | 2,171,262.93 | 8,572,227.02 | 6,381,938.85 | 5,111,642.25 |
| 加:公允价值变动收益 | 0 | - | - | -525,000 |
| 加:投资收益 | 786,063.72 | -1,126,023.46 | -719,989.9 | -587,223.62 |
| 资产处置收益 | - | 651,877.09 | - | - |
| 资产减值损失(新) | -32,754,169.06 | -57,225,565.99 | -42,848,765.28 | -40,256,933.63 |
| 信用减值损失(新) | -322,968.89 | 26,871.41 | -194,910.37 | -200,637.84 |
| 其他收益 | 5,721,865.97 | 34,429,449.19 | 11,687,929.22 | 8,709,305.2 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 78,199,642.76 | 169,407,081.21 | 212,028,534 | 169,394,062.69 |
| 加:营业外收入 | 1,430,686.98 | 1,315,564.56 | 1,041,179.63 | 682,474.83 |
| 减:营业外支出 | 13,107.18 | 2,482,823.61 | 1,893,853.62 | 1,454,179.03 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 79,617,222.56 | 168,239,822.16 | 211,175,860.01 | 168,622,358.49 |
| 减:所得税费用 | 7,134,716.48 | 5,566,718.21 | 17,208,438.78 | 13,301,081.1 |
| 六、净利润 | 72,482,506.08 | 162,673,103.95 | 193,967,421.24 | 155,321,277.39 |
| 持续经营净利润 | 72,482,506.08 | 162,673,103.95 | 193,967,421.24 | 155,321,277.39 |
| 归属于母公司股东的净利润 | 58,012,016.03 | 117,052,520.5 | 151,749,207.05 | 123,405,359.07 |
| 少数股东损益 | 14,470,490.05 | 45,620,583.45 | 42,218,214.19 | 31,915,918.32 |
| (一)基本每股收益 | 0.05 | 0.11 | 0.14 | 0.11 |
| (二)稀释每股收益 | 0.05 | 0.11 | 0.14 | 0.11 |
| 八、其他综合收益 | 883,439.22 | -121,318,766.9 | 7,551,204.85 | 6,174,818.59 |
| 归属于母公司股东的其他综合收益 | 883,439.22 | -121,318,766.9 | 7,551,204.85 | 6,174,818.59 |
| 九、综合收益总额 | 73,365,945.3 | 41,354,337.05 | 201,518,626.09 | 161,496,095.98 |
| 归属于母公司股东的综合收益总额 | 58,895,455.25 | -4,266,246.4 | 159,300,411.9 | 129,580,177.66 |
| 归属于少数股东的综合收益总额 | 14,470,490.05 | 45,620,583.45 | 42,218,214.19 | 31,915,918.32 |
| 公告日期 | 2024-04-27 | 2024-03-29 | 2023-10-28 | 2023-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |